Gloomy First Half Results For Mayne
While Restructuring Gains Pace With $90m Generics Selloff
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market